S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Buy THIS stock before Taiwan is attacked (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
Buy THIS stock before Taiwan is attacked (Ad)
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
Open vs. Anonymous Employee Feedback — Which is Better?
Buy THIS stock before Taiwan is attacked (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Buy THIS stock before Taiwan is attacked (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
Buy THIS stock before Taiwan is attacked (Ad)
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
Open vs. Anonymous Employee Feedback — Which is Better?
Buy THIS stock before Taiwan is attacked (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Buy THIS stock before Taiwan is attacked (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
Buy THIS stock before Taiwan is attacked (Ad)
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
Open vs. Anonymous Employee Feedback — Which is Better?
Buy THIS stock before Taiwan is attacked (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Buy THIS stock before Taiwan is attacked (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
Buy THIS stock before Taiwan is attacked (Ad)
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
Open vs. Anonymous Employee Feedback — Which is Better?
Buy THIS stock before Taiwan is attacked (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
NYSE:ENOV

Enovis (ENOV) Stock Forecast, Price & News

$53.25
+0.55 (+1.04%)
(As of 05/26/2023 07:00 PM ET)
Compare
Today's Range
$52.42
▼
$53.25
50-Day Range
$49.50
▼
$58.71
52-Week Range
$43.88
▼
$68.15
Volume
411,800 shs
Average Volume
420,551 shs
Market Capitalization
$2.90 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$64.88
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

Enovis MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
21.8% Upside
$64.88 Price Target
Short Interest
Healthy
3.66% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.09mentions of Enovis in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$919,241 Sold Last Quarter
Proj. Earnings Growth
22.03%
From $2.27 to $2.77 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.52 out of 5 stars

Medical Sector

154th out of 1,010 stocks

Surgical Appliances & Supplies Industry

8th out of 20 stocks

See Top Rated MarketRank™ Stocks Here

ENOV stock logo

About Enovis (NYSE:ENOV) Stock

Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.

Receive ENOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enovis and its competitors with MarketBeat's FREE daily newsletter.

ENOV Stock News Headlines

May 22, 2023 | finance.yahoo.com
Enovis (NYSE:ENOV) shareholders are still up 1.1% over 5 years despite pulling back 4.3% in the past week
May 20, 2023 | americanbankingnews.com
Enovis Co. (NYSE:ENOV) Receives Average Rating of "Moderate Buy" from Analysts
May 29, 2023 | Behind the Markets (Ad)
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"
The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>
May 17, 2023 | marketwatch.com
Catheter Stabilization Device Market Forthcoming Trends and Share Analysis by 2031
May 17, 2023 | marketwatch.com
Surgical Bone Growth Stimulator Market Share, Size, Financial Summaries Analysis from 2023-2029 with Top Players are Orthofix, Enovis, ZimVie
May 16, 2023 | americanbankingnews.com
Enovis Co. (NYSE:ENOV) Short Interest Update
May 13, 2023 | americanbankingnews.com
Enovis (NYSE:ENOV) Upgraded by Wells Fargo & Company to Overweight
May 12, 2023 | msn.com
Looking Into Enovis's Return On Invested Capital
May 29, 2023 | Behind the Markets (Ad)
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"
The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>
May 12, 2023 | msn.com
Enovis upgraded at Wells Fargo on valuation
May 11, 2023 | americanbankingnews.com
Rajiv Vinnakota Sells 1,396 Shares of Enovis Co. (NYSE:ENOV) Stock
May 10, 2023 | americanbankingnews.com
Q2 2023 Earnings Forecast for Enovis Co. (NYSE:ENOV) Issued By KeyCorp
May 8, 2023 | americanbankingnews.com
Robert W. Baird Boosts Enovis (NYSE:ENOV) Price Target to $67.00
May 5, 2023 | markets.businessinsider.com
Robert W. Baird Keeps Their Buy Rating on Enovis (ENOV)
May 4, 2023 | finance.yahoo.com
Q1 2023 Enovis Corp Earnings Call
May 4, 2023 | msn.com
Enovis Beats Q1 Earnings Estimates, Raises 2023 Guidance
May 4, 2023 | finanznachrichten.de
Enovis Corporation: Enovis Announces First Quarter 2023 Results
May 4, 2023 | finance.yahoo.com
Enovis (ENOV) Q1 Earnings and Revenues Beat Estimates
May 4, 2023 | msn.com
Enovis: Q1 Earnings Insights
May 4, 2023 | finance.yahoo.com
Enovis Announces First Quarter 2023 Results
May 3, 2023 | msn.com
Earnings Outlook For Enovis
May 2, 2023 | americanbankingnews.com
Enovis (ENOV) to Release Earnings on Thursday
April 30, 2023 | americanbankingnews.com
Enovis Co. (NYSE:ENOV) Receives $62.75 Average Price Target from Analysts
April 27, 2023 | finance.yahoo.com
Should You Invest in Enovis Corporation (ENOV) For its Ample Growth Opportunities?
April 13, 2023 | finance.yahoo.com
Enovis to Host First Quarter 2023 Results Conference Call on May 4th
April 3, 2023 | seekingalpha.com
Enovis to acquire Novastep, strengthening position in global foot and ankle market
April 3, 2023 | finance.yahoo.com
Amplitude Surgical announces the signing of a definitive agreement for the sale of Novastep's activities
See More Headlines
Receive ENOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enovis and its competitors with MarketBeat's FREE daily newsletter.

ENOV Company Calendar

Last Earnings
5/04/2023
Today
5/29/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Surgical appliances & supplies
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:ENOV
CUSIP
N/A
CIK
1420800
Web
www.enovis.com
Phone
302-252-9160
Fax
301-323-9001
Employees
6,800
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$64.88
High Stock Price Forecast
$68.00
Low Stock Price Forecast
$57.00
Forecasted Upside/Downside
+21.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.96)
Trailing P/E Ratio
N/A
Forward P/E Ratio
23.46
P/E Growth
N/A
Net Income
$-13,290,000.00
Net Margins
-3.24%
Pretax Margin
0.36%
Return on Equity
3.70%
Return on Assets
2.91%

Debt

Debt-to-Equity Ratio
0.08
Current Ratio
2.38
Quick Ratio
1.13

Sales & Book Value

Annual Sales
$1.56 billion
Price / Sales
1.86
Cash Flow
$6.34 per share
Price / Cash Flow
8.40
Book Value
$63.71 per share
Price / Book
0.84

Miscellaneous

Outstanding Shares
54,500,000
Free Float
51,717,000
Market Cap
$2.90 billion
Optionable
Optionable
Beta
2.01

Key Executives

  • Mr. Mitchell P. Rales (Age 65)
    Co-Founder & Independent Chairman
    Comp: $1
  • Mr. Matthew L. Trerotola (Age 55)
    CEO & Director
    Comp: $3.48M
  • Mr. Brady R. Shirley (Age 56)
    Pres, COO & Director
    Comp: $1.68M
  • Mr. Christopher M. Hix (Age 60)
    Exec. VP of Fin. & CFO
    Comp: $1.39M
  • Mr. Daniel A. Pryor (Age 54)
    Exec. VP of Strategy & Bus. Devel.
    Comp: $1.27M
  • Mr. John Kleckner (Age 45)
    Principal Accounting Officer
  • Mr. Michael S. Macek (Age 50)
    VP of Fin. & Investor Relations
  • Mr. Bradley J. Tandy (Age 63)
    Sr. VP & Gen. Counsel
  • Katie Sweet
    VP of Corp. Communication
  • Ms. Patricia A. Lang (Age 63)
    Sr. VP & Chief HR Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ENOV Stock - Frequently Asked Questions

Should I buy or sell Enovis stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enovis in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ENOV shares.
View ENOV analyst ratings or view top-rated stocks.

What is Enovis' stock price forecast for 2023?

9 brokerages have issued twelve-month price objectives for Enovis' shares. Their ENOV share price forecasts range from $57.00 to $68.00. On average, they expect the company's stock price to reach $64.88 in the next twelve months. This suggests a possible upside of 21.8% from the stock's current price.
View analysts price targets for ENOV or view top-rated stocks among Wall Street analysts.

How have ENOV shares performed in 2023?

Enovis' stock was trading at $53.52 at the start of the year. Since then, ENOV stock has decreased by 0.5% and is now trading at $53.25.
View the best growth stocks for 2023 here.

Are investors shorting Enovis?

Enovis saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 1,810,000 shares, a decline of 6.7% from the April 30th total of 1,940,000 shares. Based on an average trading volume of 481,900 shares, the days-to-cover ratio is currently 3.8 days. Approximately 3.7% of the company's stock are short sold.
View Enovis' Short Interest.

When is Enovis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our ENOV earnings forecast.

How were Enovis' earnings last quarter?

Enovis Co. (NYSE:ENOV) released its earnings results on Thursday, May, 4th. The company reported $0.44 earnings per share for the quarter, topping analysts' consensus estimates of $0.37 by $0.07. The firm earned $406.20 million during the quarter, compared to the consensus estimate of $389.95 million. Enovis had a negative net margin of 3.24% and a positive trailing twelve-month return on equity of 3.70%. Enovis's revenue for the quarter was up 8.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.37 EPS.

What ETFs hold Enovis' stock?

ETFs with the largest weight of Enovis (NYSE:ENOV) stock in their portfolio include First Trust Health Care AlphaDEX Fund (FXH), Invesco S&P MidCap 400 Pure Value ETF (RFV), SPDR S&P Health Care Equipment ETF (XHE), Dimensional US Small Cap Value ETF (DFSV), First Trust Active Factor Small Cap ETF (AFSM), First Trust Horizon Managed Volatility Small/Mid ETF (HSMV), Hartford Schroders ESG US Equity ETF (HEET) and VictoryShares US Small Mid Cap Value Momentum ETF (USVM).

What guidance has Enovis issued on next quarter's earnings?

Enovis issued an update on its FY 2023 earnings guidance on Thursday, May, 4th. The company provided EPS guidance of $2.18-$2.32 for the period, compared to the consensus earnings per share estimate of $2.23. The company issued revenue guidance of -.

What is Enovis' stock symbol?

Enovis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENOV."

Who are Enovis' major shareholders?

Enovis' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (9.49%), Dimensional Fund Advisors LP (5.32%), Diamond Hill Capital Management Inc. (3.97%), Thrivent Financial for Lutherans (2.86%), State Street Corp (2.70%) and Channing Capital Management LLC (2.54%). Insiders that own company stock include A Clayton Perfall, Bradley J Tandy, Brady Shirley, Christopher M Hix, Daniel A Pryor, John Kleckner, Matthew L Trerotola, Patricia A Lang, Phillip Benjamin (Ben) Berry and Rajiv Vinnakota.
View institutional ownership trends.

How do I buy shares of Enovis?

Shares of ENOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enovis' stock price today?

One share of ENOV stock can currently be purchased for approximately $53.25.

How much money does Enovis make?

Enovis (NYSE:ENOV) has a market capitalization of $2.90 billion and generates $1.56 billion in revenue each year. The company earns $-13,290,000.00 in net income (profit) each year or ($0.96) on an earnings per share basis.

How many employees does Enovis have?

The company employs 6,800 workers across the globe.

How can I contact Enovis?

Enovis' mailing address is 2711 Centerville Road Suite 400, Wilmington DE, 19808. The official website for the company is www.enovis.com. The company can be reached via phone at 302-252-9160, via email at investorrelations@colfaxcorp.com, or via fax at 301-323-9001.

This page (NYSE:ENOV) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -